Ispinesib

Drug Profile

Ispinesib

Alternative Names: 715992; CK 0238273; Ispinesib mesilate; Ispinesib mesylate; SB-715992; SB-715992-S

Latest Information Update: 13 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokinetics
  • Class Antineoplastics; Benzamides; Quinazolines; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer; Colorectal cancer; Haematological malignancies; Renal cancer; Solid tumours
  • Discontinued Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Jul 2012 The National Cancer Institute, in collaboration with GlaxoSmithKline, completes a phase II trial in Renal cancer in the US (NCT00354250)
  • 04 Nov 2010 Suspended - Phase-I for Haematological malignancies in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top